Clinical trials: Pharyngeal Cancer
Nasopharyngeal Carcinoma
De-escalation Protocols in Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to explore the efficacy and safety of image guided de-escalation protocols in patients with locoregionally advanced nasopharyngeal carcinoma (NPC).
- Trial name
- NCT04158518
- Testing
- Toxicities reduced treatment, Conventional treatment
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Chaosu Hu
Nasopharyngeal Carcinoma
Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to compare induction chemotherapy (TPF or GP) plus radiotherapy alone with induction chemotherapy plus concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma…
- Trial name
- NCT04414566
- Testing
- gemcitabine and cisplatin; docetaxel, cisplatin and fluorouracil, IMRT, IMRT and concurrent cisplatin
- Where
- China
- Volunteers
- 562 people
- Sponsor
- West China Hospital
Carcinoma, Squamous, Head and Neck Cancer
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer
Background: Bortezomib acts on molecules in head and neck cancer cells that are important for the cells growth and survival. The drug may help make the cancer more sensitive to radiation and other chemotherapy drugs.
- Conditions
- Carcinoma, Squamous, Head and Neck Cancer, Oral Cancer, Laryngeal Cancer
- Trial name
- NCT01445405
- Testing
- Bortezomib (Velcade, PS-341), Cetuximab, Cisplatin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma
A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma
This is a study to evaluate the efficacy and safety of TQB2450 injection combination with Intensity-modulated Radiotherapy in patients with inoperable locally recurrent nasopharyngeal carcinoma.
- Trial name
- NCT04895345
- Testing
- TQB2450, Intensity modulated radiotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Mouth Neoplasms, Velopharyngeal Insufficiency
A New Membrane Obturator Prothesis Concept for Soft Palate Defects
When soft palate defects lead to palatal insufficiency, the patient's quality of life is affected by difficulties swallowing, hypernasality, and poor intelligibility of speech.
- Conditions
- Mouth Neoplasms, Velopharyngeal Insufficiency, Speech Disorders, Deglutition Disorders
- Trial name
- VELOMEMBRANE (NCT04009811)
- Testing
- Suersen and membraneous obturators evaluation
- Where
- France
- Volunteers
- 4 people
- Sponsor
- University Hospital, Bordeaux
Nasopharyngeal Neoplasms, Herpesvirus 4, Human
Environmental and Genetic Determinants of NPC
Background: Nasopharyngeal carcinoma (NPC) a common malignant tumor in southern China and Southeast Asia. Infection with Epstein-Barr virus is believed to be necessary for the development of NPC; non-viral environmental factors…
- Trial name
- NCT01257100
- Where
- 6 sites in Taiwan
- Volunteers
- 3,500 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma, Intensity Modulated Radiotherapy
Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma.
The goal of this clinical trial is to compare the survival and adverse reactions differences between endoscopic surgery and intensity modulated radiotherapy for patients with newly diagnosed stage Ⅰ nasopharyngeal carcinoma…
- Conditions
- Nasopharyngeal Carcinoma, Intensity Modulated Radiotherapy, Surgery
- Trial name
- NCT06533267
- Testing
- Endoscopic nasopharyngectomy followed close follow-up, Intensity-modulated Radiotherapy
- Where
- China
- Volunteers
- 442 people
- Sponsor
- Sun Yat-sen University
Laryngeal Cancer, Hypopharyngeal Cancer
The Voice as a Tool to Detect Recurrence of Laryngeal and Hypopharyngeal Cancer
The investigators will obtain three-monthly voice recordings and fiberendoscopic examinations of the larynx/hypopharynx for a minimal period of 6 months from all laryngeal/hypopharyngeal squamous cell carcinoma (LSCC/HPSCC)…
- Trial name
- VoiceDetect (NCT05894070)
- Testing
- Voice recording, ENT (Ear, Nose and Throat) examination including transnasal fiberendoscopy, and VHI-30-questionnaire
- Where
- 2 sites in Switzerland
- Volunteers
- 100 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Nasopharyngeal Carcinoma
The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma is the most common malignant tumor of head and neck in southern China. After standard treatment, about 20% of the patients had local recurrence or distant metastasis, and the patients faced death in a…
- Trial name
- NCT04917770
- Testing
- Sintilimab in combination with Multimodality Radiotherapy
- Volunteers
- 28 people
- Sponsor
- West China Hospital
Pharynx Cancer, Larynx Cancer
Randomized Trial to Assess the Impact of a Screening Program on Upper Aerodigestive Tract Cancer Mortality in a High Risk Population
Randomized multicenter trial to assess the impact of a screening program for heavy alcohol drinkers and smokers treated in alcohol addiction clinics on upper aerodigestive tract cancer mortality.
- Conditions
- Pharynx Cancer, Larynx Cancer, Oral Cavity Cancer, Oesophageal Cancer
- Trial name
- NCT00359645
- Testing
- Screening by head and neck clinical examination with a fiberoptic nasolaryngoscopy and an oesopharyngeal brush biopsy annually during 3 years
- Where
- 35 sites in France
- Volunteers
- 1,993 people, healthy volunteers welcome
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Endocrine; Deficiency, Hypothalamo-Pituitary Disorder
Brain Irradiation for Childhood Cancer - Endocrine Monitoring During the First Years
BICHE- 1: Brain Irradiation for Childhood cancer - Endocrine monitoring during the first five years is a study of endocrine monitoring after cerebral radiotherapy.
- Conditions
- Endocrine; Deficiency, Hypothalamo-Pituitary Disorder, Radiotherapy Side Effect
- Trial name
- BIChE-1 (NCT06618703)
- Testing
- Blood sample, urine sample, osteodensitometry
- Where
- 3 sites in France
- Volunteers
- 230 people
- Sponsor
- University Hospital, Angers
Lymphedema, Oropharyngeal Cancer
Complete Decongestive Therapy (CDT) for Treatment of Head and Neck Lymphedema
Objectives: Specific Aim 1: Estimate the prevalence of head and neck lymphedema in patients who have been treated with surgery and/or radiation therapy (± chemotherapy) for oral cavity and oropharyngeal cancer.
- Conditions
- Lymphedema, Oropharyngeal Cancer, Head and Neck Cancer, Oral Cancer
- Trial name
- NCT00951470
- Testing
- Follow -Up Visits, Full CDT, Modified CDT Program
- Sponsor
- M.D. Anderson Cancer Center
Oropharynx Cancer
Feasibility of Adaptive Radiation Therapy for Human-papilloma Virus-positive Oropharyngeal Cancer Patients on MRIdian Linac
The purpose of this research is to determine whether it is feasible to treat patients with Human Papilloma Virus positive (HPV-positive) oropharyngeal tumors on a specialized treatment machine (MRIdian linear accelerator…
- Trial name
- OPC-V (NCT05849142)
- Testing
- MRIdian Linac
- Where
- United States
- Sponsor
- University of Miami
Nasopharyngeal Carcinoma (NPC)
Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
This trial aims to study the role of Ivonescimab combined with chemoradiotherapy in high-Risk locoregionally advanced nasopharyngeal carcinoma.
- Trial name
- NCT07064902
- Testing
- Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）
- Where
- 3 sites in China
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
Human Papillomavirus-Related Carcinoma, Oropharyngeal Cancer
HYHOPE: De-intensified Hypofractionated Radiation Therapy for HPV-associated Oropharynx Cancer
This is a single arm Phase I study of de-intensified hypofractionated radiation therapy for favorable human papilloma virus-associated oropharynx cancer.
- Trial name
- NCT04580446
- Testing
- Hypofractionated intensity modulated radiotherapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Texas Southwestern Medical Center
Head and Neck Cancer, Mucositis Oral
GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer
GM-CSF may protect normal cells from the side effects, such as mucositis, of radiation therapy and may help damaged tissue heal faster after radiation therapy.
- Conditions
- Head and Neck Cancer, Mucositis Oral, Radiation Toxicity, Tongue Cancer
- Trial name
- NCT00293462
- Testing
- sargramostim, oral salt and soda mouthwash
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Marilyn Dodd
Oropharyngeal Cancer
Primary Radiotherapy Versus Primary Surgery for HPV-Associated Oropharyngeal Cancer
The goal of this randomized treatment de-escalation study is to formally compare outcomes in HPV related oropharyngeal cancer tumors treated with a primary radiotherapy versus a primary surgical approach, to provide a high level…
- Trial name
- ORATOR2 (NCT03210103)
- Testing
- Radiation, Transoral Surgery (TOS) + Neck Dissection
- Where
- 9 sites in Australia, Canada
- Volunteers
- 61 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Oropharynx Cancer
Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck Squamous Cell Carcinoma
Multicentric prospective model-based de-escalation of the elective clinical target volumes (CTV) in radiotherapy of oropharyngeal carcinoma of all stages with the goal to reduce toxicity.
- Trial name
- DeEscO (NCT06563362)
- Testing
- De-escalation of irradiated volume
- Where
- 7 sites in Switzerland
- Volunteers
- 120 people
- Sponsor
- University of Zurich
Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure
This is a prospective phase II clinical trial to evaluate the efficacy and safety of apatinib and camrelizumab in recurrent or metastatic nasopharyngeal carcinoma who failed at least the first-line treatment.
- Conditions
- Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Chemotherapy Effect
- Trial name
- NCT04586088
- Testing
- Apatinib plus Camrelizumab
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Sun Yat-sen University
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement…
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT06589804
- Testing
- Biospecimen Collection, Cetuximab, Computed Tomography
- Where
- 202 sites in United States
- Volunteers
- 158 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.